Lv4
435 积分 2021-07-28 加入
New challenges and opportunities in nonclinical safety testing of biologics
26天前
已关闭
An alternative nonclinical approach to support the first-in-human clinical trial of a T-cell bispecific targeting EGFRvIII
26天前
已完结
A novel CDK8/19 inhibitor RO8323 mitigates allograft rejection through dual mechanisms of action to modulate regulatory T cell and myeloid cell
2个月前
已完结
A translational strategy employing physiologically based modelling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist
2个月前
已完结
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy
2个月前
已完结
Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy
2个月前
已完结
单克隆抗体引起细胞因子释放综合征的机制及临床前评价进展
3个月前
已完结
Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
4个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
